SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Kyrish Chuck | SVP & CFO | 2026-08-14 | Open-market buy | 1400 | $64K |
| Kyrish Chuck | SVP & CFO | 2026-08-14 | Open-market buy | 100 | $5K |
| Kyrish Chuck | SVP & CFO | 2026-08-14 | Open-market buy | 800 | $36K |
| Duffie Ashley B | SVP & GC | 2026-08-11 | Open-market buy | 600 | $27K |
| Murray Mark Christopher | SVP - Acetyls | 2026-08-11 | Open-market buy | 2153 | $98K |
| GALANTE EDWARD G | Director | 2026-08-10 | Grant/award | 1930 | $0 |
| Chinn Bruce E. | Director | 2026-05-11 | Grant/award | 2975 | $0 |
| GALANTE EDWARD G | Director | 2026-05-11 | Grant/award | 4676 | $0 |
| Hill Kathryn | Director | 2026-05-11 | Grant/award | 2975 | $0 |
| Kissire Deborah J. | Director | 2026-05-11 | Grant/award | 2975 | $0 |
| Koenig Michael | Director | 2026-05-11 | Grant/award | 2975 | $0 |
| Kuehn Christopher J | Director | 2026-05-11 | Grant/award | 2975 | $0 |
| MOORTHY GANESH | Director | 2026-05-11 | Grant/award | 2975 | $0 |
| Noonan Anne P | Director | 2026-05-11 | Grant/award | 2975 | $0 |
| Rucker Kim K.W. | Director | 2026-05-11 | Grant/award | 2975 | $0 |
| Kissire Deborah J. | Director | 2026-05-09 | D | 3376 | — |
| Koenig Michael | Director | 2026-05-09 | Tax withholding | 1013 | $58K |
| Kuehn Christopher J | Director | 2026-05-09 | D | 3376 | — |
| Rucker Kim K.W. | Director | 2026-05-09 | D | 3376 | — |
| Duffie Ashley B | SVP & GC | 2026-02-27 | Grant/award | 10431 | $0 |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
A potential covenant breach on the U.S. Revolving Credit Facility within 12 months — combined with a $346M intangible impairment, a $140M restructuring charge, and an explicit deleveraging program — marks a material deterioration in Celanese's financial risk profile. Litigation exposure has simultaneously surged with 12 new ethylene cartel claims filed by major industry counterparties, with a ruling expected Q1 2026. Risk worsening is broad-based, spanning capital structure, asset values, legal liability, restructuring, and governance.
6 company-specific · 2 common-mode
New specific closure announced: Lanaken, Belgium facility with quantified $140M charge through 2027, replacing prior Mechelen closure. Escalates restructuring risk with concrete financial impact.
We may incur significant charges or experience other significant risks and uncertainties in the event we close or divest all or part of a manufacturing plant or facility or engage in other…
Significant escalation of ethylene cartel litigation: 11 new claims filed in 2025-2026 against Celanese by major competitors (Shell, Repsol, TotalEnergies, OMV, Borealis, LyondellBasell, BASF, Dow, ExxonMobil, BP, MOL, Braskem). Preliminary hearings underway; ruling expected Q1 2026. Material increase in litigation exposure and potential damages.
Regulatory, Legal, Environmental and Tax Risks Failure to comply with applicable laws or regulations and/or changes in applicable laws or regulations may adversely affect our business and financial…
New disclosure of potential covenant breach risk: company may be unable to comply with consolidated leverage ratio covenant in U.S. Revolving Credit Facility within 12 months, requiring mitigation strategies or risking facility termination.
Risks Related to Our Indebtedness Our indebtedness and interest expense, could adversely affect us, our business flexibility, our ability to raise additional capital to fund our operations or…
Incremental $346M intangible impairment loss in 2025 vs. $117M in 2024 signals worsening asset valuation pressure in Engineered Materials segment.
We have recognized goodwill and indefinite-lived intangible asset impairment losses and may be required to recognize goodwill and indefinite-lived intangible asset impairment losses in the future. As…
Company now explicitly discloses active deleveraging initiatives and cost-reduction programs, signaling heightened debt concerns and execution risk beyond prior generic language.
We may not be able to generate sufficient cash, through normal operations, productivity and cost reduction initiatives, or otherwise, to service our indebtedness and may be forced to take other…
New disclosure of stock price decline reducing share-based award retention value and weakening compensation competitiveness—a concrete, quantifiable risk escalation.
Risks Related to Our Human Capital Our success depends upon our ability to attract and retain key employees and the identification and development of talent to succeed senior management. Our success…
New disclosure of material AI integration risks across products and operations, including litigation, regulatory uncertainty, and reputational harm exposure.
Our increasing reliance on artificial intelligence ("AI") technologies in our products, services, and operations presents risks that could adversely impact our business, financial condition, and…
Europe sales increased from 31% to 35% of net sales, amplifying exposure to adverse European economic conditions. New guidance risk disclosure added.
Risks Related to Business and Industry Conditions We are exposed to general economic, political and regulatory conditions and risks in the countries in which we have operations and customers. We…
Celanese entered into a First Amendment to its Revolving Credit Agreement on July 31, 2026, which modifies key financial covenants, increases debt baskets by $150 million, and relaxes the consolidated net leverage ratio covenant. This material modification of the Company's direct financial obligations and borrowing capacity signals potential financial stress or strategic capital needs.
View raw filing on EDGAR →Celanese Corporation issued a press release on August 4, 2026, reporting second quarter 2026 financial results, including diluted EPS of $1.15, adjusted EPS of $2.45, and net sales of $2.8 billion. The press release is attached as Exhibit 99.1 and incorporated into Item 2.02 disclosure. This is a standard quarterly earnings release with detailed segment performance, cash flow, and forward guidance.
View raw filing on EDGAR →The Item 7.01 disclosure announces that Scott A. Richardson, President and CEO, will present the Company's "financial results for its second quarter 2026" via webcast on August 5, 2026. The filing includes prepared remarks and slide presentations (Exhibits 99.1(a) and 99.1(b)) and a Non-GAAP reconciliation document (Exhibit 99.2) that explicitly references quarterly financial results and performance metrics. This is a classic earnings release disclosure, even though filed under Item 7.01 (Regulation FD) rather than Item 2.02, and is material to investors assessing the registrant's financial performance.
View raw filing on EDGAR →Celanese issued a notice of redemption for $4.777% Senior Notes due July 19, 2026, with redemption scheduled for June 25, 2026 at par plus accrued interest. While debt redemption is a routine capital management activity, the materiality depends on the principal amount outstanding (not disclosed here). The timing—redemption just before maturity—suggests refinancing or debt paydown activity that would be material to investors assessing the company's capital structure and liquidity, but the disclosure lacks sufficient detail to classify as a more specific event type.
View raw filing on EDGAR →